Eli Lilly doubles down on Oblique partnership for antibody generation [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
Building on the existing agreement from November 2023, Eli Lilly will continue to use Oblique's AbiProt platform to discover antibodies. Specifically, Sweden-based Oblique will partner with Lilly Catalyze360-ExploR&D, an arm of the company that offers clinical development capabilities for partnered biotechs and drug developers, as per a 22 August press release. The financial terms of the expanded deal were not disclosed, and neither was the target of its application. Oblique did state that if treatments are developed successfully, the partnership will “generate milestones and royalties”. Abiprot identifies therapeutic antibodies that can be programmed to have a specific pharmacological function. Oblique states its technology can help develop effective medicines against difficult-to-drug target proteins. The biotech's platform uses microfluidics and proteases as molecular probes and provides sequence and structure information for epitope identification. Oblique itself says it fo
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 [Yahoo! Finance]Yahoo! Finance
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024Business Wire
- AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "hold" rating re-affirmed by analysts at Benchmark Co..MarketBeat
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $12.00 price target on the stock, down previously from $14.00.MarketBeat
ABCL
Earnings
- 11/4/24 - Miss
ABCL
Sec Filings
- 11/14/24 - Form SC
- 11/4/24 - Form 10-Q
- 11/4/24 - Form 8-K
- ABCL's page on the SEC website